BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 21113978)

  • 1. Immunogenetics features and genomic lesions in splenic marginal zone lymphoma.
    Rinaldi A; Forconi F; Arcaini L; Mian M; Sozzi E; Zibellini S; Baldini L; Franceschetti S; Gaidano G; Marasca R; Mollejo M; Piris MA; Tucci A; Facchetti F; Bhagat G; Favera RD; Rancoita PM; Zucca E; Kwee I; Bertoni F
    Br J Haematol; 2010 Dec; 151(5):435-9. PubMed ID: 21113978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytogenetic aberrations and their prognostic value in a series of 330 splenic marginal zone B-cell lymphomas: a multicenter study of the Splenic B-Cell Lymphoma Group.
    Salido M; Baró C; Oscier D; Stamatopoulos K; Dierlamm J; Matutes E; Traverse-Glehen A; Berger F; Felman P; Thieblemont C; Gesk S; Athanasiadou A; Davis Z; Gardiner A; Milla F; Ferrer A; Mollejo M; Calasanz MJ; Florensa L; Espinet B; Luño E; Wlodarska I; Verhoef G; García-Granero M; Salar A; Papadaki T; Serrano S; Piris MA; Solé F
    Blood; 2010 Sep; 116(9):1479-88. PubMed ID: 20479288
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IGHV gene features and MYD88 L265P mutation separate the three marginal zone lymphoma entities and Waldenström macroglobulinemia/lymphoplasmacytic lymphomas.
    Gachard N; Parrens M; Soubeyran I; Petit B; Marfak A; Rizzo D; Devesa M; Delage-Corre M; Coste V; Laforêt MP; de Mascarel A; Merlio JP; Bouabdhalla K; Milpied N; Soubeyran P; Schmitt A; Bordessoule D; Cogné M; Feuillard J
    Leukemia; 2013 Jan; 27(1):183-9. PubMed ID: 22944768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Splenic marginal zone lymphoma: Clinical clustering of immunoglobulin heavy chain repertoires.
    Arcaini L; Zibellini S; Passamonti F; Rattotti S; Lucioni M; Invernizzi R; Merli M; Rizzi S; Boveri E; Rumi E; Astori C; Picone C; Varettoni M; Pascutto C; Paulli M; Lazzarino M
    Blood Cells Mol Dis; 2009; 42(3):286-91. PubMed ID: 19250848
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IGHV mutational status of nodal marginal zone lymphoma by NGS reveals distinct pathogenic pathways with different prognostic implications.
    Granai M; Amato T; Di Napoli A; Santi R; Vergoni F; Di Stefano G; Mancini V; Kovalchuk S; Cencini E; Carta AG; Aversa S; Ziepert M; Cevenini G; Lazzi S; Leoncini L; Bellan C
    Virchows Arch; 2020 Jul; 477(1):143-150. PubMed ID: 31802229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An Immunogenetic Signature of Ongoing Antigen Interactions in Splenic Marginal Zone Lymphoma Expressing IGHV1-2*04 Receptors.
    Bikos V; Karypidou M; Stalika E; Baliakas P; Xochelli A; Sutton LA; Papadopoulos G; Agathangelidis A; Papadopoulou E; Davis Z; Algara P; Kanellis G; Traverse-Glehen A; Mollejo M; Anagnostopoulos A; Ponzoni M; Gonzalez D; Pospisilova S; Matutes E; Piris MA; Papadaki T; Ghia P; Rosenquist R; Oscier D; Darzentas N; Tzovaras D; Belessi C; Hadzidimitriou A; Stamatopoulos K
    Clin Cancer Res; 2016 Apr; 22(8):2032-40. PubMed ID: 26647217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunoglobulin heavy- and light-chain repertoire in splenic marginal zone lymphoma.
    Stamatopoulos K; Belessi C; Papadaki T; Kalagiakou E; Stavroyianni N; Douka V; Afendaki S; Saloum R; Parasi A; Anagnostou D; Laoutaris N; Fassas A; Anagnostopoulos A
    Mol Med; 2004; 10(7-12):89-95. PubMed ID: 15706403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Over 30% of patients with splenic marginal zone lymphoma express the same immunoglobulin heavy variable gene: ontogenetic implications.
    Bikos V; Darzentas N; Hadzidimitriou A; Davis Z; Hockley S; Traverse-Glehen A; Algara P; Santoro A; Gonzalez D; Mollejo M; Dagklis A; Gangemi F; Bosler DS; Bourikas G; Anagnostopoulos A; Tsaftaris A; Iannitto E; Ponzoni M; Felman P; Berger F; Belessi C; Ghia P; Papadaki T; Dogan A; Degano M; Matutes E; Piris MA; Oscier D; Stamatopoulos K
    Leukemia; 2012 Jul; 26(7):1638-46. PubMed ID: 22222599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Splenic marginal zone lymphoma: characterization of 7q deletion and its value in diagnosis.
    Watkins AJ; Huang Y; Ye H; Chanudet E; Johnson N; Hamoudi R; Liu H; Dong G; Attygalle A; McPhail ED; Law ME; Isaacson PG; de Leval L; Wotherspoon A; Du MQ
    J Pathol; 2010 Mar; 220(4):461-74. PubMed ID: 20077527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A restricted IGHV gene repertoire in splenic marginal zone lymphoma is associated with autoimmune disorders.
    Brisou G; Verney A; Wenner T; Baseggio L; Felman P; Callet-Bauchu E; Coiffier B; Berger F; Salles G; Traverse-Glehen A
    Haematologica; 2014 Oct; 99(10):e197-8. PubMed ID: 24997147
    [No Abstract]   [Full Text] [Related]  

  • 11. Splenic marginal-zone lymphoma: one or more entities? A histologic, immunohistochemical, and molecular study of 42 cases.
    Papadaki T; Stamatopoulos K; Belessi C; Pouliou E; Parasi A; Douka V; Laoutaris N; Fassas A; Anagnostopoulos A; Anagnostou D
    Am J Surg Pathol; 2007 Mar; 31(3):438-46. PubMed ID: 17325486
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunoarchitectural patterns in splenic marginal zone lymphoma: correlations with chromosomal aberrations, IGHV mutations, and survival. A study of 76 cases.
    Traverse-Glehen A; Bachy E; Baseggio L; Callet-Bauchu E; Gazzo S; Verney A; Hayette S; Jallades L; Ffrench M; Salles G; Coiffier B; Felman P; Berger F
    Histopathology; 2013 May; 62(6):876-93. PubMed ID: 23611359
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of immunoglobulin genes in splenic marginal zone lymphoma suggests ongoing mutation.
    Dunn-Walters DK; Boursier L; Spencer J; Isaacson PG
    Hum Pathol; 1998 Jun; 29(6):585-93. PubMed ID: 9635678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [IGHV mutational statue in patients with splenic marginal zone lymphoma].
    Yang WJ; Yu Z; Lyu R; Li ZJ; Li H; Xiong WJ; Yi SH; Liu W; Qiu LG
    Zhonghua Xue Ye Xue Za Zhi; 2016 Sep; 37(9):774-778. PubMed ID: 27719720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and biological features of B-cell neoplasms with CDK6 translocations: an association with a subgroup of splenic marginal zone lymphomas displaying frequent CD5 expression, prolymphocytic cells, and TP53 abnormalities.
    Gailllard B; Cornillet-Lefebvre P; Le QH; Maloum K; Pannetier M; Lecoq-Lafon C; Grange B; Jondreville L; Michaux L; Nadal N; Ittel A; Luquet I; Struski S; Lefebvre C; Gaillard JB; Lafage-Pochitaloff M; Balducci E; Penther D; Barin C; Collonge-Rame MA; Jimenez-Poquet M; Richebourg S; Lemaire P; Defasque S; Radford-Weiss I; Bidet A; Susin SA; Nguyen-Khac F; Chapiro E;
    Br J Haematol; 2021 Apr; 193(1):72-82. PubMed ID: 33314017
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD5 expression identifies a subset of splenic marginal zone lymphomas with higher lymphocytosis: a clinico-pathological, cytogenetic and molecular study of 24 cases.
    Baseggio L; Traverse-Glehen A; Petinataud F; Callet-Bauchu E; Berger F; Ffrench M; Couris CM; Thieblemont C; Morel D; Coiffier B; Salles G; Felman P
    Haematologica; 2010 Apr; 95(4):604-12. PubMed ID: 20015887
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Splenic marginal-zone lymphoma: ontogeny and genetics.
    Baliakas P; Strefford JC; Bikos V; Parry M; Stamatopoulos K; Oscier D
    Leuk Lymphoma; 2015 Feb; 56(2):301-10. PubMed ID: 24798744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-throughput sequencing analysis of the chromosome 7q32 deletion reveals IRF5 as a potential tumour suppressor in splenic marginal-zone lymphoma.
    Fresquet V; Robles EF; Parker A; Martinez-Useros J; Mena M; Malumbres R; Agirre X; Catarino S; Arteta D; Osaba L; Mollejo M; Hernandez-Rivas JM; Calasanz MJ; Daibata M; Dyer MJ; Prosper F; Vizcarra E; Piris MÁ; Oscier D; Martinez-Climent JA
    Br J Haematol; 2012 Sep; 158(6):712-26. PubMed ID: 22816737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of VH genes in marginal zone lymphoma reveals marked heterogeneity between splenic and nodal tumors and suggests the existence of clonal selection.
    Traverse-Glehen A; Davi F; Ben Simon E; Callet-Bauchu E; Felman P; Baseggio L; Gazzo S; Thieblemont C; Charlot C; Coiffier B; Berger F; Salles G
    Haematologica; 2005 Apr; 90(4):470-8. PubMed ID: 15820942
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A gene is known by the company it keeps: enrichment of TNFAIP3 gene aberrations in MALT lymphomas expressing IGHV4-34 antigen receptors.
    Agathangelidis A; Xochelli A; Stamatopoulos K
    J Pathol; 2017 Dec; 243(4):403-406. PubMed ID: 28892161
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.